Dimerix is valued at it's current amount based on a 20 or 30% chance DMX-200 becomes a blockbuster CKD drug...and it's at around FV IMO. I'm still positive and will be looking to load up at prices below 0.15. Let's not kid ourselves - it's a gamble on the phase 2b results and the opportunities that may come from that, unless a bigger pharma comes in beforehand! What's the odds we're playing with? I'm with Ahmed that the opportunity is a good one relative to others in this space.
DXB- Most Undervalued Biotech on ASX?, page-18
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
-0.005(1.28%) |
Mkt cap ! $214.4M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 39.0¢ | 37.0¢ | $503.5K | 1.322M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 26318 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 170072 | 6 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |